Table 2.
The efficiency of all vaccines on both mild to moderate and severe adverse reactions based on all available literature.
| Vaccine | Mild to Moderate and Severe Adverse Reactions | Trial Location |
|---|---|---|
| Pfizer–BioNTech (BNT162b1) | ~95%/Not reported | Multinational |
| Moderna (mRNA-1273) | ~94%/~100% | Unites States |
| Sputnik V (rAd26 and rAd5) | ~92%/~100% | Russia |
| Oxford–AstraZeneca (AZD1222) [32] | ~81%/~100% | Multinational |
| Convidicea (AD5-nCOV) | Not reported | Not reported |
| Johnson & Johnson (Ad26.COV2.S) | Not reported | Not reported |
| Sinopharm (BBIBP-CorV) | Not reported | Not reported |
| Covaxin (BBV152) | Not reported | Not reported |
| Sinovac (CoronaVac) | Not reported | Not reported |